Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma

NCT ID: NCT07222345

Last Updated: 2025-11-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-31

Study Completion Date

2029-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This pilot study evaluates the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment. Preliminary efficacy of the HIIT intervention for improved cardiorespiratory fitness, body composition, physical function, autonomic response to exercise, peripheral neuropathy, biological aging markers, and physical activity will also be evaluated.

Primary Objective:

To determine the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment.

Feasibility will be assessed by:

* Participation Rate: Number of eligible survivors approached who enroll.
* Completion Rate: Number of scheduled HIIT sessions attended and number of enrolled participants who complete post-intervention testing.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hodgkin lymphoma survivors face elevated risks of cardiovascular disease and premature aging. HIIT, which alternates high-intensity effort with recovery periods, has shown benefits in adult cancer survivors but has not been tested in younger populations. This study will assess whether recently treated survivors can complete a remotely supervised 12-week HIIT program and evaluate its effects on multiple health outcomes. Participants will undergo baseline and post-intervention assessments including exercise testing, body composition, autonomic function, and blood biomarkers. The intervention is delivered via a secure web-based platform with live supervision by exercise physiologists.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hodgkin Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HIIT Intervention Group

Participants will complete a 12-week HIIT program with three 25-minute sessions per week. Each session includes warm-up, five cycles of high-intensity intervals (80-95% peak HR) and recovery periods (50-60% peak HR), and cool-down.

Group Type EXPERIMENTAL

High Intensity Interval Training (HIIT)

Intervention Type BEHAVIORAL

Participants will complete a 12-week HIIT program with three 25-minute sessions per week. Each session includes warm-up, five cycles of high-intensity intervals (80-95% peak HR) and recovery periods (50-60% peak HR), and cool-down.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

High Intensity Interval Training (HIIT)

Participants will complete a 12-week HIIT program with three 25-minute sessions per week. Each session includes warm-up, five cycles of high-intensity intervals (80-95% peak HR) and recovery periods (50-60% peak HR), and cool-down.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant has been diagnosed with Hodgkin lymphoma between the ages of 10 to 25 years.
* Participant is between the ages of \>10 and \<25 years old the time of enrollment.
* Participant has completed treatment (end of chemotherapy for those not receiving radiation therapy or end of radiation therapy) for Hodgkin lymphoma within 24 months prior to enrollment and recovered from any acute treatment-related adverse events.
* Participant has been medically cleared to participate in physical activity.
* Participant verbalizes understanding of directions for use of the web-based platform on the study provided iPad and heart rate monitor.

Exclusion Criteria

* Participant has evidence of relapsed disease.
* Participant has a diagnosis of acute heart failure.
* Participant reports currently participating in HIIT training or \>420 minutes per week of moderate to vigorous physical activity.
* Female participant who is currently pregnant.
Minimum Eligible Age

10 Years

Maximum Eligible Age

25 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

St. Jude Children's Research Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Amy Berkman, MD

Role: PRINCIPAL_INVESTIGATOR

St. Jude Children's Research Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St. Jude Children's Research Hospital

Memphis, Tennessee, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Amy Berkman, MD

Role: CONTACT

866-278-5833

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Amy Berkman, MD

Role: primary

866-278-5833

Related Links

Access external resources that provide additional context or updates about the study.

http://www.stjude.org

St. Jude Children's Research Hospital

http://www.stjude.org/protocols

Clinical Trials Open at St. Jude

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FITHOD

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.